Immunovant (IMVT) Enterprise Value (2018 - 2026)
Immunovant's (IMVT) quarterly Enterprise Value came in at -$902.1 million in Q1 2026, down 26.35% YoY from -$1.2 billion in Q1 2025, and up 9.29% on a QoQ basis from -$994.5 million in Q4 2025.
Immunovant (IMVT) Enterprise Value (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Enterprise Value data on file, last reported at -$902.1 million in Q1 2026.
- Quarterly Enterprise Value fell 26.35% year-over-year to -$902.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$902.1 million (down 26.35% YoY) and the FY2026 annual result came in at -$902.1 million, down 26.35% from the prior year.
- Enterprise Value grew to -$902.1 million in Q1 2026, from -$994.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$269.9 million in Q3 2023 to a low of -$994.5 million in Q4 2025.
- A 5-year average of -$541.2 million and a median of -$493.8 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 45.77% — and 2025, when it sank 165.42%.
- Tracing IMVT's Enterprise Value over 5 years: stood at -$432.6 million in 2022, then plunged by 59.71% to -$690.9 million in 2023, then jumped by 45.77% to -$374.7 million in 2024, then slumped by 165.42% to -$994.5 million in 2025, then climbed by 9.29% to -$902.1 million in 2026.
- The last three Enterprise Value figures came in at -$902.1 million (Q1 2026), -$994.5 million (Q4 2025), and -$521.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | -797.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -797.80 Mn |
| Mar 31, 2026 | -902.11 Mn |
| Dec 31, 2025 | -994.53 Mn |
| Sep 30, 2025 | -521.87 Mn |
| Jun 30, 2025 | -598.90 Mn |
| Mar 31, 2025 | -713.97 Mn |
| Dec 31, 2024 | -374.70 Mn |
| Sep 30, 2024 | -472.94 Mn |
| Jun 30, 2024 | -560.00 Mn |
| Mar 31, 2024 | -635.37 Mn |
| Dec 31, 2023 | -690.90 Mn |
| Sep 30, 2023 | -269.93 Mn |
| Jun 30, 2023 | -329.96 Mn |
| Mar 31, 2023 | -376.53 Mn |
| Dec 31, 2022 | -432.61 Mn |
| Sep 30, 2022 | -405.77 Mn |
| Jun 30, 2022 | -427.20 Mn |
| Mar 31, 2022 | -493.82 Mn |
| Dec 31, 2021 | -527.00 Mn |
| Sep 30, 2021 | -559.00 Mn |